Seminars in Hematology
Volume 37, Issue 1 , Pages 56-68 , January 2000

Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine

  • Norbert Frickhofen

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Norbert Frickhofen, MD, Department of Medicine III (Hematology/Oncology), HSK, Dr.-Horst-Schmidt-Kliniken GmbH, D-65199 Wiesbaden, Germany.
    • From the Department of Medicine III (Hematology/Oncology), Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany
    • From the Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    • ,
  • Stephen J Rosenfeld

      Affiliations

    • From the Department of Medicine III (Hematology/Oncology), Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany
    • From the Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA

References 

  1. Bach JF. The contribution of cyclosporine A to the understanding and treatment of autoimmune diseases. Transplant Proc. 1999;31:16S–18S
  2. Bacigalupo A, Broccia G, Corda G, et al.  Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood. 1995;85:1348–1353
  3. Bacigalupo A, Chaple M, Hows J, et al.  Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and memylprednisolone (MPred) with or without androgens: A randomized trial from the EBMT SAA working party. Br J Haematol. 1993;83:145–151
  4. Bacigalupo A, Podesta M, van Lint MT, et al.  Severe aplastic anaemia: Correlation of in vitro tests with clinical response to immunosuppression in 20 patients. Br J Haematol. 1981;47:423–432
  5. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood. 1996;87:491–494
  6. Camitta B, O'Reilly RJ, Sensenbrenner L, et al.  Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood. 1983;62:883–888
  7. Camitta BM, Doney K. Immunosuppressive therapy for aplastic anemia: Indications, agents, mechanisms, and results. Am J Pediatr Hematol Oncol. 1990;12:411–424
  8. Camitta BM, Storb R, Thomas ED. Aplastic anemia. Pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 1982;306:645–652
  9. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: A prospective randomized trial. N Engl J Med. 1983;308:113–118
  10. Champlin R, Ho W, Feig SA, et al.  Lack of efficacy for intravenous monoclonal antibody (T101) for aplastic anemia: A randomized controlled trial. Blood. 1984;64(suppl 1):132a–132a abstr
  11. Champlin RE, Ho WG, Feig SA, et al.  Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood. 1985;66:184–188
  12. Deeg HJ, Leisenring W, Storb R, et al.  Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91:3637–3645
  13. Doney K, Martin P, Storb R, et al.  A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol. 1985;13:520–524
  14. Doney K, Pepe M, Storb R, et al.  Immunosuppressive therapy of aplastic anemia: Results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. Blood. 1992;79:2566–2571
  15. Finlay JL, Toretsky J, Hoffman R, et al.  Cyclosporine A (CyA) in refractory severe aplastic anemia (AA). Blood. 1984;64(suppl 1):104a; abstr
  16. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al.  Treatment of aplastic anemia with antilymphocyte globulin and memylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297–1304
  17. Führer M, Burdach S, Ebell W, et al.  Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group. Klin Pediatr. 1998;210:173–179
  18. Gascon P, Zoumbos NC, Scala G, et al.  Lymphokine abnormalities in aplastic anemia: Implications for the mechanism of action of antithymocyte globulin. Blood. 1985;65:407–413
  19. Genestier L, Fournel S, Flacher M, et al.  Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood. 1998;91:2360–2368
  20. Gluckman E, Devergie A, Poros A, et al.  Results of immuno-suppression in 170 cases of severe aplastic anaemia. Report of the European Group of Bone Marrow Transplant (EGBMT). Br J Haematol. 1982;51:541–550
  21. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al.  Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992;79:2540–2546
  22. Gluckman E, Rokicka-Milewska R, Gordon-Smith EC, et al.  Results of a randomized study of glycosylated rHuG-CSF lenograstim in severe aplastic anemia. Blood. 1999;92(suppl 1):376a; abstr
  23. Gordon-Smith EC, Yandle A, Milne A, et al.  Randomized placebo controlled study of rh-GM-CSF following ALG in the treatment of aplastic anemia. Bone Marrow Transplant. 1991;7(suppl 2):78–80
  24. Griner PF. A survey of the effectiveness of cyclophosphamide in patients with severe aplastic anemia. Am J Hematol. 1980;8:55–60
  25. Hinterberger-Fischer M, Höcker P, Lechner K, et al.  Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure. Eur J Haematol. 1989;43:136–142
  26. Jansen J, Gratama JW, Zwaan FE, et al.  Therapy with monoclonal antibody OKT3 in severe aplastic anemia. Exp Hematol. 1984;12(suppl 15):46–47
  27. Kaltwasser JP, Dix U, Schalk KP, et al.  Effect of androgens on the response to antithymocyte globulin in patients with aplastic anaemia. Eur J Haematol. 1988;40:111–118
  28. Keisu M, Heit W, Lambertenghi-Deliliers G, et al.  Transient pancytopenia. A report from the International Agranulocytosis and Aplastic Anemia Study. Blut. 1990;61:240–244
  29. Leonard EM, Raefsky E, Griffith P, et al.  Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol. 1989;72:278–284
  30. Marsh J, Schrezenmeier H, Marin P, et al.  Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93:2191–2195
  31. Mathé G, Amiel JL, Schwarzenberg L, et al.  Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 1970;2:131–136
  32. Matloub YH, Bostrom B, Golembe B, et al.  Antithymocyte globulin, cyclosporine, and prednisone for the treatment of severe aplastic anemia in children. A pilot study. Am J Pediatr Hematol Oncol. 1994;16:104–106
  33. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation. 1998;65:1481–1489
  34. Najean Y, Haguenauer O. Long-term (5 to 20 years) evolution of nongrafted aplastic anemia. Blood. 1990;76:2222–2228
  35. Najean Y, Pecking A, LeDanvic M. Androgen therapy of aplastic anemia—A prospective study of 352 cases. Scand J Haematol. 1979;22:343–356
  36. Nimer SD, Golde DW, Kwan K, et al.  In vitro production of granulocyte-macrophage colony-stimulating factor in aplastic anemia: Possible mechanisms of action of antithymocyte globulin. Blood. 1991;78:163–168
  37. Platanias L, Gascon P, Bielory L, et al.  Eymphocyte phenotype and lymphokines following antithymocyte globulin therapy in patients with aplastic anemia. Br J Haematol. 1987;66:437–443
  38. Prud'homme GJ, Parfrey NA, Vanier EE. Cyclosporine-induced autoimmunity and immune hyperreactivity. Autoimmunity. 1991;9:345–356
  39. Raefsky EL, Gascon P, Gratwohl A, et al.  Biological and immunological characterization of ATG and ALG. Blood. 1986;68:712–719
  40. Raghavachar A, Ganser A, Freund M, et al.  Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia. Cytokines Mol Ther. 1996;2:215–223
  41. Raghavachar A, Kolbe K, Höffken K, et al.  Standard immunosuppression is superior to cyclosporine/filgrastim in severe aplastic anemia: The German multicenter study. Bone Marrow Transplant. 1999;23(suppl 1):S31–S31 abstr
  42. Rosenfeld SJ, Young NS. Aplastic anemia treated by immuno-suppression is a chronic relapsing illness, but prognosis is unaffected. Blood. 1997;90(suppl 1):435a–435a abstr
  43. Schrezenmeier H, Hertenstein B, Wagner B, et al.  A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol. 1995;23:81–87
  44. Schrezenmeier H, Hinterberger W, Hows J, et al.  Second immunosuppressive treatment of patients with aplastic anaemia not responding to the first course of immunosuppression (IS): A report from the Working Party on Severe Aplastic Anaemia of the EBMT. Bone Marrow Transplant. 1995;15(suppl 2):10; abstr
  45. Schrezenmeier H, Marin P, Raghavachar A, et al.  Relapse of aplastic anaemia after immunosuppressive treatment: A report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol. 1993;85:371–377
  46. Schrezenmeier H, Schlander M, Raghavachar A. Cyclosporin A in aplastic anemia—Report of a workshop. Ann Hematol. 1992;65:33–36
  47. Schwinger W, Urban C, Lackner H, et al.  Treatment of aplastic anemia with a monoclonal antibody directed against the interleukin-2 receptor. Ann Hematol. 1993;66:181–184
  48. Speck B, Gluckman E, Haak HL, et al.  Treatment of aplastic anemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet. 1977;2:1145–1148
  49. Speck B, Gratwohl A, Nissen C, et al.  Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J. 1981;282:860–863
  50. Speck B, Kissling M. Successful bone marrow grafts in experimental aplastic anemia using antilymphocytic serum for conditioning. Rev Eur Etudes Clin Biol. 1971;16:1047–1051
  51. Stryckmans PA, Dumont JP, Velu T, et al.  Cyclosporine in refractory severe aplastic anemia. N Engl J Med. 1984;310:655–656 (letter)
  52. Sugano N, Ito K, Murai S. Cyclosporin A inhibits H2O2-induced apoptosis of human fibroblasts. FEBS Lett. 1999;447:274–276
  53. Taniguchi Y, Frickhofen N, Raghavachar A, et al.  Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines. Eur J Haematol. 1990;44:244–251
  54. Tichelli A, Passweg J, Nissen C, et al.  Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 1998;100:393–400
  55. Tichelli A, Socie G, Henry-Amar M, et al.  Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med. 1999;130:193–201
  56. Tong J, Bacigalupo A, Piaggio G, et al.  Effect of antilymphocyte globulin (ALG) on bone marrow T/non-T cells from aplastic anaemia patients and normal controls. Br J Haematol. 1989;73:546–550
  57. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol. 1998;10:507–512
  58. Weinberger M, Elattar I, Marshall D, et al.  Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine. 1992;71:24–43

PII: S0037-1963(00)90030-1

Seminars in Hematology
Volume 37, Issue 1 , Pages 56-68 , January 2000

Article Tools